Eribulin versus S-1 as first or second-line chemotherapy to assess health-related quality of life and overall survival in HER2-negative metastatic breast cancer (RESQ study): a non-inferiority, randomised, controlled, open-label, phase 3 trial
| Autor: | Takahashi, Masato, Kikawa, Yuichiro, Kashiwabara, Kosuke, Taira, Naruto, Iwatani, Tsuguo, Shimozuma, Kojiro, Ohtani, Shoichiro, Yoshinami, Tetsuhiro, Watanabe, Junichiro, Kashiwaba, Masahiro, Watanabe, Ken-ichi, Kitada, Masahiro, Sakaguchi, Koichi, Tanabe, Yuko, Aihara, Tomohiko, Mukai, Hirofumi |
|---|---|
| Zdroj: | In eClinicalMedicine August 2024 74 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|